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The suPARnosticTM ELISA kits were gifts from ViroGates (Birkeroed, Denmark)
Clinical Impact Statement: The ability to predict the clinical course of parapneumonic effusions would 
be invaluable to physicians when making management decisions at diagnosis. In this prospectively 
collected cohort a raised pleural suPAR was highly predictive of patients who went on to receive more 
invasive management of parapneumonic effusions and added value to conventional biomarkers.
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ABSTRACT
Rationale: Parapneumonic effusions have a wide clinical spectrum. The majority settle with conservative 
management but some progress to complex collections requiring intervention.  For decades, physicians 
have relied on pleural fluid pH to determine the need for chest tube drainage despite a lack of prospective 
validation and no ability to predict the requirement for fibrinolytics or thoracic surgery. 
Objectives: To study the ability of soluble urokinase Plasminogen Activator Receptor (suPAR), a potential 
biomarker of pleural fluid loculation, to predict the need for invasive management compared to 
conventional fluid biomarkers (pH, glucose, LDH) in parapneumonic effusions. 
Methods: Patients presenting with pleural effusions were prospectively recruited to an observational 
study with biological samples stored at presentation. Pleural fluid and serum suPAR levels were measured 
using the suPARnosticTM double-monoclonal antibody sandwich ELISA on 93 patients with parapneumonic 
effusions and 47 controls (benign and malignant effusions). 
Measurements and Main Results: Pleural suPAR levels were significantly higher in effusions that loculated 
versus non-loculated parapneumonic effusions (median 132ng/ml vs 22ng/ml, p<0.001). Pleural suPAR 
could more accurately predict the subsequent insertion of a chest tube with an AUC of 0.93 (95%CI. 0.89-
0.98) compared to pleural pH (AUC 0.82, 95%CI. 0.73-0.90). suPAR was superior to the combination of 
conventional pleural biomarkers (pH, glucose and LDH) when predicting the referral for intrapleural 
fibrinolysis or thoracic surgery (AUC 0.92 vs 0.76). 
Conclusions: Raised pleural suPAR was predictive of patients receiving more invasive management of 
parapneumonic effusions and added value to conventional biomarkers. These results need validation in a 
prospective multicenter trial. 
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INTRODUCTION
The clinical spectrum of pleural effusions related to infection is wide. From simple parapneumonic 
effusions that settle with conservative management, through to grossly septated fibropurulent collections 
needing chest tube drainage, intrapleural fibrinolytics or thoracic surgery for resolution. The process by 
which an effusion progresses down this cascade has been the subject of much research but the ability to 
predict which patients will require more aggressive intervention remains elusive (1). In 1980, Light et al 
proposed the use of a pleural fluid pH cut-off of 7.2 to indicate the need for chest tube drainage on the 
basis that as bacteria metabolise and neutrophils phagocytose the pleural pH falls. (2) This cut off is 
referenced in the majority of international guidelines despite never being prospectively validated (3-5). 
A defining feature in the spectrum of parapneumonic effusions is the dysregulation of the 
fibrinogenesis/fibrinolytic cascade and the subsequent development of loculations within the effusion. 
Loculations prevent adequate chest tube drainage, impede source control, can result in long term 
respiratory compromise and might even reduce the effectiveness of antibiotics (6). Pleural fluid pH, 
although a mainstay of initial management decisions, does not predict the development of loculations. A 
biomarker called soluble urokinase Plasminogen Activator Receptor (suPAR) is theoretically a more 
appropriate guide for management. suPAR is the soluble form of uPAR which, once bound to endogenous 
urokinase (uPA), catalyses the conversion of plasminogen to plasmin (a potent fibrinolytic). Originally 
documented in the plasma, serum and urine of patients with human immunodeficiency virus (HIV), 
pneumonia, sepsis, tuberculosis and various solid-tumours (7), more recent studies have shown suPAR 
also rises in infected ascitic and pleural fluid (8-11). 
We aimed to assess the potential role of pleural fluid suPAR in the investigation and subsequent 
management of parapneumonic effusions using a prospectively collected cohort of patients. 
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Some of the results of this study have been previously reported in the form of an abstract (12). 
METHODS
Patients
Between 2009 to 2016, patients presenting to a UK tertiary pleural service with undiagnosed pleural 
effusions requiring a diagnostic thoracentesis were prospectively recruited to an observational study 
(08/H0102/11). All had routine serum and pleural fluid analysis including a full blood count, serum C-
reactive protein (CRP) and pleural fluid pH, glucose and lactate dehydrogenase (LDH). At the time of 
pleural fluid sampling, pleural ultrasound was performed by a physician at least Level 1 BTS ultrasound 
trained (or equivalent) with the presence of loculations documented. Repeat ultrasounds or computed 
tomography (CT) scans were performed if clinically indicated and the development of loculations was 
recorded. Patients gave consent for storage of their baseline pleural fluid and serum samples in a -70oC 
freezer for future analysis. 
Patients were followed up at 1 year to ascertain the final diagnosis of their pleural effusion, which was 
decided by two independent respiratory consultants based on pre-specified criteria (see Appendix 1). 
Patients were otherwise treated as per standard care, see Appendix 2 for local guidelines on 
parapneumonic effusion management.
suPAR testing 
Pleural fluid and serum samples were analysed from patients with an effusion secondary to infection. 
Those with frank pus on thoracentesis were excluded on the grounds that management for those cases is 
unequivocal. All patient samples were handled in accordance with a standardized study protocol; see 
Appendix 3 for full sample processing details and validation experiments of different sample preparation 
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methods. suPAR levels were analysed in duplicate (mean value presented, with high correlation observed 
(R2>0.99)) using the suPARnostic® AUTO Flex ELISA assay according to the manufacturer’s protocol 
(Virogates, Denmark). This assay detects free suPAR (as well as domains II and III), it does not capture 
suPAR-scuPA (suPAR bound to single chain urokinase) or suPAR-scuPA-PAI-1 (suPAR-scuPA bound to 
plasminogen activator inhibitor-1) complexes (13). As per protocol, samples were diluted until they fell 
within the workable range of the assay (0.2-15 ng/ml). 
In order to explore suPAR levels in other aetiologies, selected controls from the same cohort were also 
analysed including;
1. transudative effusions secondary to congestive cardiac failure or hepatic hydrothorax, 
2. non-loculated malignant effusions, 
3. loculated malignant effusions, 
4. malignant effusions that were simple at baseline but became loculated at later timepoints 
receiving intrapleural fibrinolytics (urokinase). 
Statistical analysis 
Patient data are reported as the median/interquartile range (IQR)/range for continuous variables. The 
statistical differences between groups were analysed using a non-parametric Mann–Whitney U-test. 
The correlation between serum/pleural suPAR and conventional biomarkers (including serum CRP and 
neutrophils, pleural pH, LDH, glucose and protein) was assessed using Spearman’s rank correlation 
coefficient (with p<0.05 used to define statistical significance). Multivariable binomial logistic regression 
was used to compare clinical outcomes to biochemical markers. The accuracy of suPAR and other 
conventional markers as diagnostic tests was assessed using standard sensitivity, specificity, positive and 
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negative likelihood ratios (PLR and NLR) and area under the curve (AUC) statistics with 95% confidence 
intervals. DeLong’s test was performed to compare the differences in AUCs. Statistical analysis was 
performed using SPSS 24.0 statistical software (Chicago, IL, USA), receiver operating characteristic (ROC) 
curve graphs were generated using RStudio 3.6.1 (R Foundation for Statistical Computing, Vienna). 
RESULTS
Between 2009 to 2016, 93 patients presenting to our centre with pleural effusions secondary to infection 
(excluding frank pus) were recruited and had biological samples stored. As controls, 31 cases of malignant 
effusions and 16 transudative effusions were also included in this analysis. The median age of patients 
with parapneumonic effusions was 66 and there was a male predominance. Full patient demographics by 
aetiology are represented in Table 1. 
Pleural suPAR levels in all effusions 
The median pleural suPAR of pleural effusions varied significantly by aetiology, with parapneumonic 
effusions having significantly higher levels than malignancy and transudative effusions at baseline (p= 
<0.01). Pleural suPAR was strongly correlated with the commonly used pleural fluid indicators of infection: 
pH (Correlation coefficient (CC) -0.576 p<0.01), glucose (CC -0.632 neg p<0.01) and LDH (CC 0.596 p<0.01), 
but not pleural fluid protein (CC 0.057 p= 0.59) across all aetiologias.
Pleural suPAR in parapneumonic effusions
Table 2 shows the levels of pleural and serum suPAR from patients with parapneumonic effusions 
alongside routine pleural fluid and serum tests depending on the presence/absence of fluid loculation 
during hospital admission. Levels of pleural suPAR were significantly higher in loculated versus non-
loculated effusions (p<0.01).  Using a cut-off of 35 ng/ml pleural suPAR had a 100% sensitivity (95% C.I. 
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91-100) for predicting pleural fluid loculations with a specificity of 91% (95% C.I. 80-97), PLR of 12.3 and 
NLR of 0.0. This compared to pleural pH which, using the conventional cut-off of 7.2, had a sensitivity of 
52% (95% C.I. 37-68), specificity of 84%(95% C.I. 70-93), PLR of 3.2 and NLR of 0.57, see Figure 1. In a 
multivariable analysis model, including all the analytes presented in Table 2, pleural suPAR was the only 
independent predictor of pleural effusion loculation during hospital admission, see Appendix 4.
In 9 patients where the initial ultrasound was simple, loculations developed on subsequent pleural 
ultrasound and/or CT scans at a median of 5 days (range 3-10). The baseline pleural suPAR was 
significantly higher in parapneumonic effusions that subsequently loculated (median 139.6 ng/ml, IQR 
41.9-312.8) compared to those that remained non loculated (median 22.3, IQR 14.0-28.1) and was 
equivalent to effusion that were loculated from baseline (median 131.0, IQR 52.7-223.8)  (p<0.01). 
Serum suPAR in parapneumonic effusions
Paired serum suPAR levels were not correlated with pleural suPAR within parapneumonic effusions (CC 
0.170 p=0.11), nor any other pleural fluid marker or fluid loculation. Serum suPAR was correlated with 
serum CRP (CC 0.268 p< 0.01) and serum neutrophils (CC 0.233 p=0.03) but not clinical outcomes. 
Pleural suPAR and chest tube insertion for parapneumonic effusions
Of the conventional pleural fluid markers for predicting chest tube insertion (pH, glucose and LDH), pleural 
pH was the most accurate (AUC 0.82 C.I. 0.73-0.90, sensitivity 54%, specificity 95%, PLR 10.5 and NLR 0.5 
using 7.2 as a cut-off). Pleural suPAR (alone) was superior to pleural pH (alone) at predicting the insertion 
of a chest tube for drainage of infected pleural effusions (AUC 0.93, C.I. 0.89-0.98, p=0.01 using DeLong’s 
test). Using a cut-off of 35ng/ml, pleural suPAR had an 83% sensitivity, 92% specificity, PLR 10.8 and NLR 
0.2 (see Figure). In a multivariable logistic regression, pleural pH (p=0.02), pleural LDH (p=0.05), a 
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neutrophilic effusion (p=0.05) and pleural suPAR (p=0.01) were significant indicators for chest tube 
insertion, see Appendix 4). 
Pleural suPAR and referral for medical/surgical rescue therapies
Pleural suPAR was superior to all other conventional markers combined at predicting the need for rescue 
therapies (intrapleural fibrinolytics or thoracic surgery) with an AUC of 0.92 (0.87-0.98, p=0.02 using 
DeLong’s test). Using a cut-off of 65ng/ml, pleural suPAR was 94% sensitive and 84% specific (PLR 6.0, NLR 
0.1) at predicting the referral for these therapies (16 of the 93 patients), see Table 3.
The combination of markers that are conventionally used to define a complex parapneumonic effusion 
(including pleural pH < 7.2 OR pleural glucose ≤ 3.0 mmol/L (≤ 55mg/dL) OR pleural LDH >1000 IU/L)(4) 
had an AUC of 0.76 (0.71-0.81) for predicting rescue therapies, see Figure 3. Pleural suPAR was the only 
significant baseline predictor of rescue therapies (p =0.01), see Appendix 4. 
Pleural suPAR in malignant effusions
Pleural suPAR levels were significantly higher in malignant effusions that were loculated at the time of 
pleural fluid analysis (p< 0.01). We carried out a further analysis to assess whether baseline pleural suPAR 
levels could predict future malignant loculations. The ‘Delayed Loculation’ group included effusions that 
started out non-loculated (simple) and became loculated (over a period of 4-6 months). Baseline pleural 
suPAR levels were non-significantly higher in the delayed loculation group compared to those that 
remained non-loculated (p-0.19).
DISCUSSION
In this prospectively recruited cohort of patients presenting with parapneumonic effusions, high pleural 
suPAR could predict the insertion of a chest tube with an AUC of 0.93 (95% CI. 0.89-0.98). It could predict 
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the presence or development of loculations with considerable accuracy. A high pleural suPAR was also 
indicative of the referral for intrapleural fibrinolytics and/or thoracic surgery and was superior to 
conventional pleural fluid biomarkers. 
The optimal management of parapneumonic effusions is contentious and the topic of several ongoing 
research studies. Much of the uncertainty relates to the difficulty predicting which patients require formal 
drainage of their effusion and which will resolve with conservative management (antibiotics) alone. 
Guidelines recommend formal drainage in the case of frank pus or a positive gram stain/culture of pleural 
fluid (3, 4). Given low culture rates of fluid from complex parapneumonic effusions (14), formal drainage 
is also recommended if the pleural fluid pH is less than 7.2. This threshold was first suggested by Light in 
1980 after a case series of 90 patients showed that low pH effusions (n=10) tended to need chest tube 
drainage (2). In 1995, Heffner and colleagues performed an elegant meta-analysis of the studies relating 
to the topic of using pleural pH, glucose or LDH in distinguishing complicated and uncomplicated 
parapneumonic effusions (5). From the 7 included studies (251 patients) they concluded that pleural pH 
was the best performing analyte at a cut-off of 7.21. However, they also recognised that given the 
observational nature of the 7 studies, and the fact that this analyte had become ‘entrenched in clinical 
practice’, it required ‘validation in well-designed prospective studies’. pH falls due to lactic acid and carbon 
dioxide production by bacteria within the pleural space (15, 16). Although indicating the presence of 
bacteria it is prone to both false positive and negatives in the need for invasive pleural management and 
has never been prospectively validated in this regard (17). 
A crucial factor in the management of parapneumonic effusions is the development of pleural thickening, 
septations and loculations. The tendency for loculation development is not only associated with more 
severe infection; it also reduces the likely success of simple fluid drainage versus the need for more 
invasive medical (e.g. intrapleural fibrinolytics) or surgical therapies. Again, a low pleural pH is more likely 
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in loculated effusions (18) but is inaccurate as it is a sequalae of numerous biochemical reactions, not 
simply the derangement of normal fibrinolysis (19) so cannot be used as an indicator for fibrinolytics or 
surgery. Other markers to predict which patients might require more invasive management of their 
parapneumonic effusion have been elusive. Pleural fluid biomarkers such as procalcitonin (20), C-reactive 
protein (21) and calprotectin (22) have been tested in parapneumonic effusions but given these markers 
focus on neutrophilic activation and/or general increased in chemo-cytokine activity they are no more 
specific than pH in prognostication. Recent studies have tested cytokines involved in the production of 
pleural fluid (23) but less have focused on those related to loculation development for which suPAR seems 
a more specific target. 
Loculations develop due to derangement of the normal fibrinolysis cascade mediated by the urokinase-
type plasminogen activator system, see Figure 5. This is composed of a proteinase called urokinase-type 
plasminogen activator (uPA), a cell bound uPA receptor (uPAR) and suPAR. suPAR, the soluble form of 
uPAR, is a glycoprotein with a molecular weight of 55–60 kDa. uPAR is cleaved from its 
glycosylphosphatidylinositol (GPI) anchor by various proteases related to infection and inflammation. The 
uPA system is involved in pericellular proteolysis, cell migration and tissue remodeling. Most notably, uPA 
once bound to uPAR, catalyzes the conversion of plasminogen into plasmin, a potent endogenous 
fibrinolytic. It has been demonstrated in both animal models and humans that the development of pleural 
loculations is related to levels of plasminogen activator inhibitor-1 (PAI-1) which is released by pleural 
mesothelial cells (24). PAI-1 inhibits uPA and therefore the conversion of plasminogen as well as 
suppressing the activity of several other endogenous and therapeutic fibrinolytics. Given these 
pathological roles it is logical that PAI-1 itself could serve as a biomarker of pleural organization; however, 
this is limited by the instability and variation of the enzyme (25). We have shown that in parapneumonic 
effusions pleural suPAR is dramatically raised in the presence or even future development of pleural 
loculations. The biological role of suPAR in pleural fluid are less well understood. While neutrophil bound 
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uPAR is inversely correlated with suPAR levels in critically ill patients, ((26) binding of single chain uPA 
(scuPA) to suPAR increases its PA activity suggesting that suPAR can augment pleural fluid plasminogen 
activator activity and plasmin generation (27). This interaction could localize plasminogen activation 
within pleural fluid, similar to that which occurs at cell surfaces(28). Measurement of suPAR could 
potentially provide a method to assess the capacity of pleural fluids to support uPA-related plasminogen 
activator activity. The MIST-2 trial demonstrated that the combination of intrapleural alteplase and DNase 
improved radiographic appearance, reduced hospital length of stay and surgical referral rates in pleural 
infection (29). However, uncertainty persists around patient selection and optimal timing of both 
fibrinolytics and surgical intervention given the difficulty of predicting the course of pleural infection at 
baseline. Given its ability to predict the development of complicated effusions, suPAR may be an 
opportunity to use biomarkers in lung precision medicine to identify which patients are likely to require 
admission for drainage and early rescue treatments, addressing a “specific clinical unmet need” (30). 
The higher levels of pleural suPAR in loculated effusions of a malignant aetiology compared to non-
loculated suggest that malignant locule development follows a similar fibrinogenesis cascade. Levels were 
lower in loculated malignant effusions compared to loculated parapneumonic effusions suggesting the 
process is more subacute in malignancy. However, there were several cases where malignant effusions 
had pleural suPAR levels similar to loculated parapneumonic effusions limiting its utility as a diagnostic 
test in the sometimes-challenging clinical situation of distinguishing an advanced malignant effusion from 
infection. We also tested the ability of pleural suPAR to predict the development of loculations within 
malignant effusions that were simple at baseline. Levels were non-significantly higher in the delayed 
loculation group and given the small numbers involved this relationship needs further investigation. 
This study has some limitations that may affect the generalisability of its findings. Although suPAR levels 
were done en-bloc and therefore researchers were blind to the results, the other biochemical results (pH, 
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LDH, glucose) were part of clinical care so would have affected a physician’s management. This is a 
weakness of all research that has attempted to study the true utility of pleural pH and may actually 
strengthen the conclusions of the suPAR results. The decision to insert a chest tube is influenced by many 
different biochemical and radiological factors and may vary according to the treating physician. Despite 
this, pleural suPAR was the most accurate baseline variable (including all biochemical and radiological 
markers), at identifying patients who went on to have a chest tube or rescue therapies. Secondly, some 
of the clinical outcomes such as fibrinolytic use and surgical referral may have been confounded by other 
factors not related to the pleural infection alone. The recently presented PILOT study has demonstrated 
that a significant proportion of patients with the most serious pleural infection do not go on to have 
surgery due to frailty and/or comorbidity (31). Additionally, the routine use of the fibrinolytic agents 
tPA/DNase was not adopted for several years into this study’s recruitment. Both factors may explain why 
many patients with a high pleural suPAR did not have fibrinolytics or surgery, although the biomarker was 
highly specific for these rescue therapies. Thirdly, suPAR levels were measured on clinical samples that 
had been frozen for up to 10 years (median 6 yrs). However, serum suPAR levels have been shown to be 
resistant to up to 8 freeze-thaw cycles and stable over a 5 year period limiting the impact on this analysis 
(32, 33). Finally, the urgent nature of pleural infection treatment means that any biomarker should be 
able to be analysed rapidly. This study used the commercial suPARnostic® ELISA which would not fulfil this 
requirement. However, more rapid analytical platforms are available including a suPARnostic® Quick 
Triage point of care device or turbidimetric assay (suPARnostic® TurbiLatex). 
In conclusion, the management of parapneumonic effusions has been dictated by crude measures of 
inflammation and bacterial replication for decades. The urokinase-type plasminogen activator system 
plays a key role in the development of pleural loculations and is a theoretically promising target of study. 
This prospective cohort study demonstrated that high pleural fluid suPAR levels are strongly correlated 
with the development of loculations in parapneumonic effusions as well as subsequent invasive 
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management including chest tube drainage, fibrinolytics and thoracic surgery. A comprehensive 
assessment of the utility of pleural suPAR in parapneumonic effusions requires a prospective multicenter 
trial of suPAR guided management versus standard care.
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FIGURE LEGENDS
Figure 1. Pleural fluid pH against pleural suPAR by fluid loculation (intercepts at pH = 7.2 and suPAR 
35ng/ml). 
Figure 2. ROC curves of pleural markers to predict insertion of a chest tube, plus boxplot of pleural 
suPAR and insertion of chest tube. 
Figure 3. ROC curves of conventional pleural biomarkers combined (pH, glucose, LDH) and the 
additional benefit of pleural suPAR at predicting the use of fibrinolytics/surgery, plus boxplot of 
pleural suPAR and use of fibrinolytics/surgery.
Figure 4. Boxplot of pleural suPAR levels in malignant effusions.
Figure 5. The biology of suPAR and the urokinase-type plasminogen activator system.
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TABLES







Age, median (IQR) 66 (46-78) 68 (61-79) 74 (62-86)
Male/Female (%) 57/36 (61/39) 19/12 (61/39) 10/6 (63/37)
Serum, median (IQR)
Neutrophils (x109/L) 8.50 (6.45-12.09) 6.0 (4.46-6.94) 4.41 (2.88-5.69)
CRP (mg/L) 119.0 (56.5-210.9) 29.0 (5.9-72.4) 20.5 (8.3-55.2)
Pleural fluid, median 
(IQR)
pH 7.32 (7.06-7.41) 7.41 (7.32-7.47) 7.53 (7.43-7.71)
Protein (g/L) 44 (36-51) 45 (32-50) 20 (13-27)
LDH (IU/L) 679 (432-1493) 476 (309-768) 176 (137-217)
Glucose (mmol/L) 5.3 (3.5-6.5) 5.5 (3.3-6.7) 7.3 (6.4)
Pleural suPAR (ng/ml)
       [range]
36.9 (20.2-124.1)
     [9.1-644]
15.0 (9.4-26.7)
     [3.0-68.0]
12.0 (8.2-13.8)
     [8.2-18.3]
IQR- Interquartile range, CRP- C reactive protein, LDH- Lactate dehydrogenase, suPAR- soluble 
urokinase Plasminogen Activator Receptor. 
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Pleural pH 7.4 (7.28-7.44) 7.14 (6.88-7.33) <0.01
Pleural Protein (g/L) 45 (38-51) 40.0 (34.3-50.0) 0.98
Pleural LDH (IU/L) 516 (330-747) 1276 (657-2794) <0.01
Pleural Glucose (mmol/L) 5.7 (4.95-6.90) 3.45 (0.2-5.3) <0.01
Pleural suPAR (ng/ml)
     [range]
22.3 (14.0-28.1)
     [9.1-42.3]
132.2 (52.3-229.2)
     [36.9-614.0]
<0.01*
Serum Neutrophils (x109/L) 7.00 (5.51-10.32) 10.1 (7.56-13.77) <0.01
Serum CRP (mg/L) 96.3 (46.0-150.3) 139.1 (75.1-247.2) 0.01
Serum suPAR (ng/ml)
     [range]
4.64 (3.66-6.41)
     [2.02-16.90]
6.12 (3.95-7.96)
     [1.94-20.9]
0.22
LDH- Lactate Dehydrogenase, suPAR- soluble urokinase Plasminogen Activator Receptor, CRP- C reactive 
protein. 
*Significant on multivariable analysis, see Appendix 4. 
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Table 3. Median pleural suPAR and conventional biomarker levels by clinical outcomes 
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Pleural pH 7.46 (7.43-7.50) 7.39 (7.32-7.44) 7.33 (7.18-7.53)
Pleural suPAR (ng/ml) 10.7 (7.3-14.0) 17.4 (12.3-25.2) 36.5 (21.9-51.3)
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Figure 1. Pleural fluid pH against pleural suPAR by fluid loculation (intercepts at pH = 7.2 and 
suPAR 35ng/ml). 
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Figure 2. ROC curves of pleural markers to predict insertion of a chest tube, plus boxplot of pleural 
suPAR and insertion of chest tube. 
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Figure 3. ROC curves of conventional pleural biomarkers combined (pH, glucose, LDH) and the 
additional benefit of pleural suPAR at predicting the use of fibrinolytics/surgery, plus boxplot of 
pleural suPAR and use of fibrinolytics/surgery.
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Figure 4. Boxplot of pleural suPAR levels in malignant effusions
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Figure 5. The biology of suPAR and the urokinase-type plasminogen activator system. 
Normal physiology
1.Endogenous single chain urokinase (scuPA) is converted to the more active two chain uPA (tcuPA) by binding to cell bound uPA 
receptor (uPAR)
2. tcuPA readily converts plasminogen to plasmin
3. Plasmin promotes fibrinolysis, activates matrix metalloproteinases and converts further scuPA to tcuPA.
Pathological state
4. In response to proinflammatory stimuli, various cytokines, other mediators and plasminogen activator inhibitor 1 (PAI-1) are 
upregulated. PAI-1 inhibits scuPA bound to uPAR or suPAR, tcuPA and tissue plasminogen activator (not shown) thereby decreasing 
local fibrinolysis. 
5. Inflammatory proteases cleave the glycosyl phosphatidylinositol (GPI) anchor to generate soluble uPAR (suPAR). 
6. suPAR exerts several functions including binding of scuPA or tcuPA or their complexes with PAI-1, regulation of cellular migration, 
adhesion and proliferation.
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Online Data Supplement
Appendix 1; Standardised Diagnostic criteria for pleural effusions (North Bristol 
Pleural Investigation Study (08/H0102/11)). Online Data Supplement.
Malignant
Malignant pleural fluid cytology or biopsy
        or
Histologically confirmed pulmonary/extra-thoracic malignancy with radiographic 
evidence of metastasis to ipsilateral pleura on CT.
        or
Radiological changes meeting Leung’s criteria which have progressed in keeping with 
malignancy on interval CT scan in the correct clinical context (1).
       or
Autopsy confirming pleural malignancy 
Empyema
Clinical presentation suggestive of sepsis/infection
And (one or more of the following)
a/. Pleural fluid gram stain or culture positive
or
b/. Frank pus on pleural aspiration
Complicated parapneumonic effusion (CPE)
Clinical presentation suggestive of sepsis/infection (and follow up for at least 6 
months inconsistent with pleural malignancy)
And (one or more of the following)
a/. Pleural fluid pH ≤7.2 
or
b/. Pleural fluid glucose ≤ 3.0 mmol/L
or
b/. Pleural fluid LDH > 1000 IU/L (upper limit of serum LDH is 480 U/L)
Simple Parapneumonic effusion (SPE)
Clinical presentation suggestive of sepsis/infection with appropriate chest radiology 
and pleural fluid which does not fulfil the criteria for empyema or CPE (above)
       And
Resolution of effusion on CXR after antibiotics 
Connective tissue disease (including RA)
Systemic features or known diagnosis of connective tissue disease
       And
chest radiology (including CT imaging) showing benign features (eg doesn’t meet any 
of Leung’s criteria) with at least 6 months follow-up  and /or pleural biopsy negative 
for malignancy.
Pulmonary embolism
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Evidence of PE on CTPA  
       And
No alternative explanation for pleural effusion on cross sectional imaging or pleural 
fluid analysis. (where the CT shows no evidence of pleural thickening – which would 
suggest another cause) 
       
BAPE or diffuse pleural thickening due to asbestos
History of asbestos exposure or evidence of pleural plaques on CT
       And
a/. Stable or improving CT appearances with follow-up for at least 12 months.( The 
development of enfolded lung is allowed)
       or
b/. Negative thoracoscopy  (benign pleural biopsy)
Congestive Cardiac Failure (CCF)
History and examination features of CCF
       or
Evidence of at least moderate LV systolic or diastolic failure or severe valvular 
disease on echo
or
Improvement of effusion and symptoms with diuretic therapy
Coronary artery bypass graft (CABG) effusion
CABG in 3 months prior to development of pleural effusion in the absence of an 
alternative cause
Hepatic hydrothorax
Known history or clinical presentation consistent with liver disease
       And 
Recurrent transudative pleural effusion
       And
Negative cytology
Renal failure or hypoalbuminaemia
Biochemical confirmation of renal failure or hypoalbuminaemia  in the absence of 
clinical, radiological or pleural fluid analysis suspicious of an alternative cause.
TB pleuritis
Culture or Acid-alcohol-fast-bacilli (AAFB) positive sputum, pleural fluid or pleural 
tissue
       And
Resolution of pleural effusion with anti TB therapy at 6 month follow-up.
Inflammatory pleuritis (Non-specific pleuritis)
Demonstration of non-specific inflammatory pleuritis on pleural biopsy 
       And
Presentation not in keeping with parapneumonic effusion (see above)
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       And
Follow-up for 12 months without progression that would suggest a malignant cause.
Undiagnosed
Exhaustive investigations including 12 months follow-up with interval CT scans has 
not demonstrated a diagnosis
       or
Patient unfit for further investigation and follow up
       or
Patient died without definitive diagnosis and no post mortem examination 
conducted
 Reference
 1. Leung, A.N., N.L. Muller, and R.R. Miller, CT in differential diagnosis of diffuse 
pleural disease. AJR Am J Roentgenol, 1990. 154(3): p. 487-92.
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Appendix 2. Parapneumonic effusion management
Indication for chest tube insertion for parapneumonic effusions
Chest tube insertion should be considered for the following indications; 
Clinical presentation consistent with parapneumonic effusion AND fulfilling at least one of 
the following criteria;
 Purulent pleural fluid
 Pleural fluid pH ≤ 7.2
 Pleural fluid glucose ≤ 3.0 mmol/L
 Pleural fluid lactate dehydrogenase (LDH) > 1000 IU/L
 Pleural fluid gram stain and/or culture positive for bacteria
If, despite not meeting the above criteria, the patient fails to respond to initial medical 
therapy with ongoing markers of infection/sepsis then chest tube drainage should be 
reconsidered. 
Indication for intrapleural fibrinolytics
Intrapleural fibrinolytics (tPA 5mg and DNase 5mg delivered via the chest tube) should be 
considered after a minimum of 24-48hours chest tube drainage. 
Assuming no contraindications to treatment, intrapleural fibrinolytics should be considered 
when:
 Thoracic ultrasound imaging has revealed pleural fluid septation or loculation which 
is felt to be clinically important
 The chest tube has stopped draining but there remains a clinically important residual 
effusion on chest radiograph/CT scan/pleural ultrasound
 The patient continues to show clinical or biochemical signs of infection despite good 
chest tube drainage and appropriate antibiotic therapy
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Indication for thoracic surgical referral
Referral to the thoracic surgeons, if appropriate, should be considered if:
 intrapleural fibrinolytics have failed to result in clinical improvement 
 intrapleural fibrinolytics are contraindicated in the context of failed chest tube 
drainage (above criteria)
 the degree of fluid complexity precludes the use of chest drainage or fibrinolytic 
therapy
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Appendix 3. Sample handing protocol and additional experiments on the effect of sample 
collection tubes and centrifugation.
Sample handling protocol for main analysis
Pleural fluid samples
 Pleural fluid collected at diagnostic thoracentesis into plain (non-heparinized/non-
citrated) collection tubes
 Pleural fluid centrifuged for 20minutes at 1000G 
 Supernatant pipetted into 1.5ml Eppendorf tubes (pellet discarded)
 Samples stored at -70oC for future analysis or immediately processed. 
Blood samples
 Blood samples collected by venepuncture at the time of diagnostic thoracentesis 
into serum separator gel bottle (yellow-top). 
 Blood sample left to rest upright for 30 mins
 Blood sample centrifuged for 20minutes at 1000G 
 Following centrifugation, the liquid supernatant (serum) is transferred into 1.5ml 
Eppendorf tubes
 Samples stored at -70oC for future analysis or immediately processed. 
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Impact of collection tube type on suPAR results 
A subset of 8 patients had pleural fluid and blood collected using plain (gold top serum 
separator tubes for blood), sodium-citrate (blue) and EDTA (lavender) tubes. 




Pleural fluid samples were spun at 1000G for 20minutes as per our protocol shown above 
and the supernatant collected and frozen at -70oc prior to en-bloc analysis. 
For both pleural fluid and blood samples suPAR levels were analysed using the suPARnostic 
ELISA in duplicate. 
Figure A&B; Line graphs of suPAR level depending on sample collection tube.  A-Pleural fluid, 
B- Blood
For pleural fluid there was slight variation in pleural suPAR levels with a slight increase in 
levels using EDTA tubes.
For blood samples there was no significant variation in suPAR levels depending on the 
collection tube type, see Figure B. 
A B
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Impact of centrifuge speed on pleural suPAR results 
To test the impact of varying centrifuge speed on pleural suPAR levels, 3 patients with 
parapneumonic effusions had pleural fluid collected at diagnosis. Pleural fluid was collectd 
in plain tubes (as per the protocol for the main analysis) and centrifuged at 3 different 
speeds for 20 minutes before analysis (as well as a tube that was not spun at all). The 
supernatant was collected and anlaysed using the suPARnostic ELISA in duplicate. 
There was no significant difference between the samples but there was a trend towards 
increasing suPAR levels as the centriuge spin was increased, see Figure C. 
Figure C; Boxplot of pleural suPAR levels for 3 patients depending on centrifuge speed at 
sample collection.
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Appendix 4. Multivariable binomial logistic regression tables 
Baseline predictors of parapneumonic effusion loculation development (n=93)
Factor   Regression 
Estimate 
Std. Error z value p-value  
Pleural suPAR 0.5688 0.2763 2.059   0.0395
Pleural Glucose -0.0531 0.4815 -0.110   0.9122  
Pleural protein -0.2707 0.2093 -1.293   0.1959  
Pleural LDH -0.0001 0.0016 -0.076   0.9397  
Pleural pH 1.9691 4.3523 0.453   0.6509  
Serum Neutrophils -0.3383 0.5496 -0.616   0.5381  
Serum CRP 0.0022 0.0165 0.131   0.8956
Serum suPAR 0.2745 0.2894 0.949   0.3427
suPAR- soluble urokinase Plasminogen Activator Receptor, LDH- lactate dehydrogenase, CRP- C 
reactive protein
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Baseline predictors of chest tube insertion in parapneumonic effusions (n=93)
Factor   Regression 
Estimate
Std. Error z value p-value  
Pleural pH                       -6.4282 2.6101   -2.463   0.0138
Pleural Protein                    0.04990   0.0600   0.831   0.4061
Pleural LDH                       -0.0025   0.0012  -2.005   0.0450
Pleural Glucose                  -0.1338  0.1888  -0.709   0.4786  
Neutrophilic 
effusion*
4.3911   2.2373   1.963   0.0497
Pleural suPAR                     0.2965   0.1214   2.442   0.0146
Serum neutrophils   -0.2042   0.1768  -1.155   0.2482
Serum CRP 0.0121   0.0076   1.581   0.1139
Serum suPAR 0.2023
 
0.2743 0.737   0.4609
Effusion size on chest 
radiograph (over 50% 
of hemithorax)
2.3041 1.4473   1.592   0.1114
Loculation on 
baseline ultrasound
2.7099 2.0081   1.349   0.1772
suPAR- soluble urokinase Plasminogen Activator Receptor, LDH- lactate dehydrogenase, CRP- C 
reactive protein, * Defined as >50% neutrophils on pleural differential cell count
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Baseline predictors of rescue therapy (fibrinolytics or surgery) in parapneumonic effusions 
(n=93)
Factor   Regression 
Estimate
Std. Error  z value p-value  
Pleural pH                       -1.2451 3.1952 -0.390   0.6968  
Pleural Protein                    0.1028
 
0.0669 1.537  0.1243  
Pleural LDH                       0.0001 0.0001 0.449 0.6537  
Pleural Glucose                  -0.1338 0.2618 -0.511   0.6094  
Neutrophilic 
effusion* 
-4.0691  -2.4064 -1.691 0.0908
Pleural suPAR                     0.0157
 
0.0062 2.540   0.0111
Serum neutrophils 
(x10^9)  
0.0230  0.0796 0.289 0.7727  
Serum CRP 0.0074  0.0075 0.979   0.3278
Serum suPAR 0.1810 0.1958 0.924   0.3552  
Effusion size on chest 
radiograph (over 50% 
of hemithorax)
0.5352 1.0530 0.508   0.6113  
Loculation on 
baseline ultrasound
2.7061 1.7652  1.533   0.1252  
suPAR- soluble urokinase Plasminogen Activator Receptor, LDH- lactate dehydrogenase, CRP- C reactive 
protein, * Defined as >50% neutrophils on pleural differential cell count 
Page 42 of 42
 AJRCCM Articles in Press. Published February 18, 2020 as 10.1164/rccm.201911-2169OC 
 Copyright © 2020 by the American Thoracic Society 
